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BH3 domain of BID induces potent and selective apoptosis of 
non-small cell lung cancer cells: mechanisms and implications for 
therapy
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Apoptosis resistance is a hallmark of cancer and contributes to chemo-
resistance particularly in non-small cell lung cancer (NSCLC). Mul-
tidomain protapoptotic proteins BAX and BAK are critically regulate 
apoptosis through mitochondrial outer membrane permeabilization 
(MOMP), however their regulation at the NSCLC mitochondrial sur-
face has not been explored. The death-inducing BH3 domain of the ca-
nonical BAX/BAK activator BID, when coupled to an N-octoarginine 
cell delivery moiety, triggered rapid mitochondrial depolarization (MD) 
in NSCLC but not bronchial epithelial cells (BECs). Carboxyﬂuoresce-
in conjugation of BH3BID conﬁrmed rapid uptake into both cell types. 
MD was completely prevented by mutation of BH3BID (L90®A). 
Isolated NSCLC but not BEC mitochondria released cytochrome C 
within 15 minutes of BH3BID followed by SMAC. BAK conformation 
change an N terminus exposure was only induced in NSCLC mito-
chondria. BH3BID induced MD in a sequence dependent manner in 
isolated NSCLC mitochondria with marked alteration in mitochondrial 
ultrastructure, and was inhibited by double siRNA knockdown of BAX 
and BAK, by exogenous cytochrome C, or by mitochondrial apoptosis 
channel blocker (±)-1-(3,6-Dibromocarbazol-9-yl)-3-piperazin-1-yl-
propan-2-ol, bis TFA. Artiﬁcally induced MOMP (by digitonin permea-
bilization), was sufﬁcient to induce MD, consistent with uncoupling 
of electron transport following subtotal mitochondrial cytochrome C 
release. Although NSCLC but not BEC mitochondria expressed several 
antiapoptotic BCL-2 family proteins (BCL-2, BCL-XL, MCL-1, A1) 
and endogenous activator BH3 proteins BID and BIM, their double 
knockdown by siRNA did not inhibit BH3BID induced MD in NSCLC 
mitochondria. Crosslinked NSCLC mitochondria conﬁrmed both 
monomeric and high molecular weight complexes of BAX and BAK. 
In conclusion, BH3BID selectively kills NSCLC cells by targeting 
mitochondrial BAX and BAK and does not require BH3 proteins for 
toxicity. This pharmacology may be therapeutically exploitable as a 
means of achieving targeted NSCLC apoptosis. 
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Coagulation/fibrinolysis activation in advanced non small cell lung 
cancer: tumor invasion or venothrombotic complication
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Haemostatic abnormalities are found in the most of patients with 
advanced cancer, including lung cancer. Because there is a growing 
number of observations concerning the potential of anticoagulant 
agents to prolong survival in tumor patients, a detailed characterization 
of haemostatic markers in lung cancer is needed. 
The aim of our study was to explore whether the activation of coagula-
tion/ﬁbrinolysis 
is more a marker of tumor stage or venothrombotic complications in 
patients with advanced non-small cell lung cancer (NSCLC).
In 92 patients mean aged 61 years ±8,21 with NSCLC stage IIIB/IV 
venous ultrasound (VUS)was performed before chemotherapy. We 
measured in our patients concentration of D-dimer, tissue factor (TF), 
tissue factor pathway inhibitor (TFPI), thrombin -activatable ﬁbrynoly-
sis inhibitor (TAFI), plasmiongen activator inhibitor type-1 and type-2 
(PAI-1 and PAI-2) and urokinase-type plasminogen activator receptor 
(uPAR). The measurements of these markers were performed in 24 
healthy controls as well.
None of our patients with NSCLC had signs of proximal venous leg 
thrombosis in VUS. The mean values of measured parameters are listed 
in table 1. D-dimer and TF levels were signiﬁcantly elevated in NSCLC 
pts whereas TAFI levels were normal though higer than in controls.
 NSCLC pts SD controls SD
normal 
values
D-dimer 
ng/ml
831 476 380 150 <500
TF pg/ml 394 249 211 137 <255
TFPI pg/ml 1160 232 798 235 148-834
TAFI ug/ml 9,2 4,47 7,32 3,04 4-15
PAI -1 ng/ml 105 35 63,3 37,5 2-47
PAI-2 ng/ml not  detectable     
uPAR 1,15 0,96   <0,1
Conclusion: Signiﬁcant activation of TF pathway and plasminogen 
cascade observed in patients with advanced NSCLC is probably related 
to adnanced tumor stage than to thrombotic complication. PAI-1 acts 
synergistic to u-PAR in promotion of cancer invasion, in contrast to 
PAI-2, which was undetectable in our patients.
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Crowding makes a lung cancer cell line grow slower
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Background: The hypothesis of this study was that modulation of 
space affects proliferation rate in cancer cells allowing it to adapt to 
changing environment.
Materials and Methods: A squamous cell carcinoma cell line, U-
1752, was tested. Subcultivating was performed twice a week, during 
three weeks preserving 1/3, 1/5, 1/7 and 1/10 respectively. The experi-
ment was performed in duplicates. 
Via plotting the cell number as if all cells had been preserved at each 
subcultivation a doubling time for each subcultivation group was 
obtained. The fraction of proliferating cells was studied immunohisto-
chemically with antibodies against Ki67.
Results: The results showed a doubling time of 52 hours in the 1/3 
subcultivation group. The doubling time was gradually shorted in each 
group and when 1/10 of the cells were spared the doubling time was 
only 30 hours.
